

# Curriculum Vitae

**Name: Tai Yeon, Koo**

**Office Address:**

Department of Nephrology and Hypertension, Korea University Anam Hospital  
73 Goryeodae-ro, Seongbuk-gu, Seoul, 02841, South Korea

**E-mail: marvin77@empas.com**

**Education**

1997.3-2003.2 Medical Doctor College of Medicine, Hanyang University, Seoul, Korea  
2006.3-2008.2 Master's degree College of Medicine, Hanyang University, Seoul, Korea  
2009.3-2013.2 Doctor's degree College of Medicine, Hanyang University, Seoul, Korea

**Training**

2003/03 - 2004/02	Hanyang University Hospital	Internship
2005/03 - 2009/02	Internal Medicine, Hanyang University Hospital	Residency
2009/03 - 2010/02, 2011/03 - 2012/02	Division of Nephrology, Internal Medicine, Hanyang University Hospital	Fellowship
2010/03 - 2011/02	Division of Nephrology, Internal Medicine, Asan Medical Center	Fellowship
2012/03 - 2014/08	Transplantation Center, Seoul National University Hospital	Fellowship
2015/03 - 2016/02	Transplantation Center, Seoul National University Hospital	Assistant professor
2016/03 - 2016/07	Transplantation Center, Seoul National University Hospital	Research professor
2016/08 - 2017/02	Internal Medicine, Asan Medical Center	Hospitalist
2017/03 - 2019/09	Transplantation Center, Seoul National University Hospital	Research professor

2019/10 - 2022/03	Internal Medicine, Seongnam Citizens Medical Center	
2022/04 - Present	Department of Nephrology and Hypertension, Korea University Anam Hospital	Clinical associate professor

### License and Certification

- 2003 Medical Doctor, Seoul, Korea
- 2009 Board of Internal Medicine, Seoul, Korea
- 2010 Board of Dialysis, Seoul, Korea
- 2011 Board of Nephrology, Seoul, Korea

### Professional Societies

- 02-03-2009 Korean Association of Internal Medicine Member
- 02-03-2010 Korean Society of Nephrology Member
- 04-04-2012 Korean Society for Transplantation Member

### Published Articles

1. Presence of a survival benefit of HLA-incompatible living donor kidney transplantation compared to waiting or HLA-compatible deceased donor kidney transplantation with a long waiting time. Koo TY, Lee JH, Min SI, Lee Y, Kim MS, Ha J, Kim SI, Ahn C, Kim YS, Kim J, Huh KH, Yang J. *Kidney Int.* 2021;100(1):206-214.
2. Better health-related quality of life in kidney transplant patients compared to chronic kidney disease patients with similar renal function. Ryu JH, Koo TY, Ro H, Cho JH, Kim MG, Huh KH, Park JB, Lee S, Han S, Kim J, Oh KH, Yang J; KNOW-KT Study group. *PLoS One.* 2021;16(10):e0257981
3. The tacrolimus metabolism affect post-transplant outcome mediating acute rejection and delayed graft function: analysis from Korean Organ Transplantation Registry data. Ro H, Jeong JC, Kong JM, Min JW, Park SK, Lee J, Koo TY, Yang J, Kim MS, Hwang S, Ahn C. *Transpl Int.* 2021;34(1):163-174
4. Development of the Asian Transplant Registry under the Asian Society of Transplantation. Jeong JC, Yuzawa K, Shroff S, Danguilan R, Koo TY, Thwin KT, Lkhaakhuu OE, Yang J, Kim MS, Ahn C, Ro H. *Transplant Proc.* 2020;52 (6):1634-1638.

5. Granulocyte Colony-Stimulating Factor Attenuates Renal Ischemia-Reperfusion Injury by Inducing Myeloid-Derived Suppressor Cells. Yan JJ, Ryu JH, Piao H, Hwang JH, Han D, Lee SK, Jang JY, Lee J, Koo TY, Yang J. *Kidney Res Clin Pract* 2019;38(4): 499-508.
6. Anti-CD45RB Antibody Therapy Attenuates Renal Ischemia-Reperfusion Injury by Inducing Regulatory B Cells. Fang T, Koo TY, Lee JG, Jang JY, Xu Y, Hwang JH, Park S, Yan JJ, Ryu JH, Ryu YM, Kim SY, Suh KS, Yang J. *Am Soc Nephrol* 2019;30(10): 1870-1885.
7. Identification of Human B-1 Helper T Cells with a Th1-Like Memory Phenotype and High Integrin CD49d Expression. Lee JG, Jang JY, Fang T, Xu Y, Yan JJ, Ryu JH, Jeon HJ, Koo TY, Kim DK, Oh KH, Kim TJ, Yang J. *Front Immunol.* 2018;9:1617.
8. Role of Human CD200 Overexpression in Pig-to-Human Xenogeneic Immune Response Compared With Human CD47 Overexpression. Yan JJ, Koo TY, Lee HS, Lee WB, Kang B, Lee JG, Jang JY, Fang T, Ryu JH, Ahn C, Kim SJ, Yang J. *Transplantation.* 2018;102(3):406-416.
9. Renal Allograft Function is a Risk Factor of Left Ventricular Remodeling after Kidney Transplantation. Koo TY, Ahn C, Yang J. *Transplant Proc.* 2017;49 (5):1043-1047.
10. The P2X7 receptor antagonist, oxidized adenosine triphosphate, ameliorates renal ischemia-reperfusion injury by expansion of regulatory T cells. Koo TY, Lee JG, Yan JJ, Jang JY, Ju KD, Han M, Oh KH, Ahn C, Yang J. *Kidney Int.* 2017;92(2):415-31.
11. Poor predictability of QuantiFERON-TB assay in recipients and donors for tuberculosis development after kidney transplantation in an intermediate-TB -burden country. Jambaldorj E, Han M, Jeong JC, Koo TY, Min SI, Song EY, Ha J, Ahn C, Yang J. *BMC Nephrol.* 2017;18(1):88.
12. IL-2/anti-IL-2 complexes ameliorate lupus nephritis by expansion of CD4(+)CD25(+)Foxp3(+) regulatory T cells. Yan JJ, Lee JG, Jang JY, Koo TY, Ahn C, Yang J. *Kidney Int.* 2017;91(3):603-15.
13. Pre-transplant Evaluation of Donor Urinary Biomarkers can Predict Reduced Graft Function After Deceased Donor Kidney Transplantation. Koo TY, Jeong JC, Lee Y, Ko

- KP, Lee KB, Lee S, Park SJ, Park JB, Han M, Lim HJ, Ahn C, Yang J. *Medicine (Baltimore)*. 2016;95(11):e3076.
14. Outcomes of dialysis and the transplantation options for patients with diabetic end-stage renal disease in Korea. Jeon HJ, Koo TY, Han M, Kim HJ, Jeong JC, Park H, Ha J, Kim SJ, Ahn C, Park JB, Yang J. *Clin Transplant*. 2016;30(5):534-44.
  15. Current progress in ABO-incompatible kidney transplantation. Koo TY, Yang J. *Kidney Res Clin Pract*. 2015;34(3):170-9.
  16. Initial report of the Korean Organ Transplant Registry: the first report of national kidney transplantation data. Ahn C, Koo TY, Jeong JC, Kim M, Yang J, Lee J, Min SI, Lee JE, Kim MS, Kwon OJ, Kim SJ, Kim YH, Kim YH, Choi BS, Choi SJ, Lee DH, Chung SY, Cho WH, Kim YS; Korean Organ Transplantation Registry Study Group. *Transplant Proc*. 2014;46(2):425-30.
  17. Utility of QuantiFERON-TB assay for prediction of tuberculosis development in kidney transplant patients in intermediate- tuberculosis-burden country: lack of evidence for enhanced prediction for short-term tuberculosis development. Jeong JC, Koo TY, Jeon HJ, Park HC, Ryu HJ, Lee JP, Min SI, Hwang YH, Ha J, Ahn C, Yang J. *Transplant Proc*. 2014;46(2):583-7.
  18. Protective Effect of Peptide-GV1001 against Renal Ischemia-Reperfusion Injury in Mice. Koo TY, Yan J, Yang J. *Transplant Proc*. 2014;46(4):1117-22.
  19. IL-2/anti-IL-2 complex attenuates renal ischemia-reperfusion injury through expansion of regulatory T cells. Kim MG, Koo TY, Yan JJ, Lee E, Han KH, Jeong JC, Ro H, Kim BS, Jo SK, Oh KH, Surh CD, Ahn C, Yang J. *J Am Soc Nephrol*. 2013;24(10):1529-36.
  20. Mycophenolic acid regulates spleen tyrosine kinase to repress tumour necrosis factor-alpha-induced monocyte chemotactic protein-1 production in cultured human aortic endothelial cells. Koo TY, Kim YJ, Yang WS, Park JS, Han NJ, Lee JM, Park SK. *Cell Biol Int*. 2013; 37(1):19-28.
  21. Clinicopathologic Features of IgA-Dominant Postinfectious Glomerulonephritis. Koo TY, Kim GH, Park H. *Korean J Pathol*. 2012; 46(2):105-14.

Signature/Date: Tai Yeon Koo, 2022/10/14